Tango Therapeutics, Inc. — fact timeline

Robert Azelby was appointed as Director at Tango Therapeutics, Inc..

“the Board appointed Robert Azelby as a director of the Company to fill the newly created vacancy on the Board resulting from the increase to the board size.”

Tango Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC and Leerink Partners LLC as representatives (effective 2026-06-09).

“On June 9, 2026, Tango Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC and Leerink Partners LLC as representatives (the “Representatives”) to the several underwriters named in the Underwriting Agreement (collectively, the “Underwriters”), relating to an underwritten offering (the “Offering”) of (i) 18,166,667 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 1,833,395 shares of Common Stock”

Tango Therapeutics, Inc. shareholders approved Non-binding advisory vote to approve named executive officer compensation at the 2026-06-04 meeting.

“The Company's stockholders approved the non-binding, advisory vote on the compensation of the Company's named executive officers.”

Tango Therapeutics, Inc. shareholders approved Ratification of the selection of PricewaterhouseCoopers, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-04 meeting.

“The selection of PricewaterhouseCoopers, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified.”

Tango Therapeutics, Inc. shareholders approved Election of Mace Rothenberg, M.D. as Class II director at the 2026-06-04 meeting.

“Malte Peters, M.D. and Mace Rothenberg, M.D. were duly elected to the Company's Board as Class II directors.”

Tango Therapeutics, Inc. shareholders approved Election of Malte Peters, M.D. as Class II director at the 2026-06-04 meeting.

“Malte Peters, M.D. and Mace Rothenberg, M.D. were duly elected to the Company's Board as Class II directors.”

Tango Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.

“On May 13, 2026, Tango Therapeutics, Inc. (“Tango” or the “Company”) issued a press release relating to its results of operations and financial condition for the quarter ended March 31, 2026.”

Sung Lee was appointed as Lead Independent Director, Chairperson of the Compensation Committee, Member of NCG Committee at Tango Therapeutics, Inc..

“the Board appointed Sung Lee as Lead Independent Director of the Board and the Chairperson of the Compensation Committee and as a member thereof, each effective as of May 13, 2026.”

Kanishka Pothula resigned as Director, Member of the Nominating and Corporate Governance Committee at Tango Therapeutics, Inc..

“Also on May 12, 2026, Kanishka Pothula resigned from the Board and as a member of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), in each case effective as of May 13, 2026.”

Alexis Borisy resigned as Director, Lead Independent Director, Chairperson of the Compensation Committee at Tango Therapeutics, Inc..

“On May 12, 2026, Alexis Borisy resigned from the Company’s Board of Directors (the “Board”), as Lead Independent Director of the Board, and as the Chairperson of the Compensation Committee of the Board (the “Compensation Committee”) and as a member thereof, in each case effective as of May 13, 2026.”

Daniella Beckman departed as Chief Financial Officer at Tango Therapeutics, Inc..

“on April 10, 2026, the board of directors (the “Board”) of Tango Therapeutics, Inc. (the “Company”) determined that Daniella Beckman will no longer serve as the Company’s Chief Financial Officer, principal accounting officer and principal financial officer, effective as of April 15, 2026.”

Tango Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2025.

“Collaboration revenue was $0 for the three months ended December 31, 2025, compared to $5.4 million for the same period in 2024, and $62.4 million for the twelve months ended December 31, 2025, compared to $30.0 million for the same period in 2024.”

Tango Therapeutics, Inc. terminated Open Market Sales Agreement SM (Jefferies Sales Agreement) with Jefferies LLC valued at termination of the 2022 ATM Program under which the Company could sell up to $100,000,000 of shares (effective 2025-11-21).

“On November 18, 2025, the Company delivered written notice to Jefferies to terminate the Jefferies Sales Agreement, effective as of November 21, 2025, pursuant to Section 7(b)(i) thereof.”

Tango Therapeutics, Inc. entered into Sales Agreement with Leerink Partners LLC valued at up to $100,000,000 of shares of common stock (effective 2025-11-21).

“On November 21, 2025, Tango Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (the “Agent”), pursuant to which the Company may sell, from time to time, at its option, shares of the Company’s common stock, $0.001 par value per share (the “Shares”), through the Agent, as sales agent (the “ATM Offering”).”

Tango Therapeutics, Inc. issued 1,732,101 shares of common stock to a certain accredited investor for $8.66 per share.

“the Company also entered into a securities purchase agreement (the “Purchase Agreement”) with a certain accredited investor (the “Purchaser”), for the private investment in public equity (the “Private Placement”) of 1,732,101 shares (the “PIPE Shares”) of the Company’s Common Stock, at a purchase price of $8.66 per share.”

Tango Therapeutics, Inc.: Amendment to increase authorized shares of common stock from 200,000,000 to 400,000,000 (effective 2025-06-05).

“The certificate of amendment of the Company’s Second Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”), was filed with the Secretary of State of the State of Delaware on June 5, 2025 and became effective upon filing.”

Tango Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: revenue $6.5 million, net income $37.9 million, EPS $0.35 per share.

“held $343.6 million in cash, cash equivalents and marketable securities, which the Company expects to be sufficient to fund operations into late 2026. Collaboration revenue was $6.5 million for the three months ended March 31, 2024, compared to $5.8 million for the same period in 2023. Research costs incurred under the collaboration were similar during each of the”

Tango Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

“On March 18, 2024, Tango Therapeutics, Inc. (Tango or the Company) issued a press release relating to its results of operations and financial condition for the quarter and year ended December 31, 2023.”

Tango Therapeutics, Inc. reported financial results for third quarter ended September 30, 2023.

“On November 8, 2023, Tango Therapeutics, Inc. (Tango or the Company) issued a press release relating to its results of operations and financial condition for the quarter ended September 30, 2023.”

John Ketchum was appointed as Director (Class III) at Tango Therapeutics, Inc..

“Effective August 29, 2023, the Board appointed John Ketchum as a director of the Company to fill the newly created vacancy on the Board resulting from Mr. Davis’s resignation.”

Aaron Davis resigned as Member of the Board of Directors, Class III director at Tango Therapeutics, Inc..

“On August 28, 2023, Aaron Davis, a member of the Board of Directors of Tango Therapeutics, Inc. (the “Company”), serving as a Class III director, notified the Company that he is resigning from the Company’s Board of Directors (the “Board”), effective immediately.”

Tango Therapeutics, Inc. entered into Purchase Agreement with purchasers named therein valued at approximately $80 million (effective 2023-08-10).

“On August 10, 2023 Tango Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of (i) 13,196,671 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at $5.15 per Share, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase 2,340,579 shares of Common Stock (the “Warrant Shares” and together with the Shares and the Pre-Funded Warrants, the “Securities”), at a purchase price of $5.1499 per Pre-Funded Warrant.”

Tango Therapeutics, Inc. reported financial results for second quarter ended June 30, 2023.

“On August 7, 2023, Tango Therapeutics, Inc. (Tango or the Company) issued a press release relating to its results of operations and financial condition for the quarter ended June 30, 2023.”

Alan Huang changed role as Chief Scientific Officer at Tango Therapeutics, Inc..

“On August 3, 2023, Alan Huang, Ph.D., the Company's Chief Scientific Officer, notified the Company that he intends to transition out of his role as Chief Scientific Officer.”

Tango Therapeutics, Inc. shareholders approved Ratification of the selection of PricewaterhouseCoopers, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-06 meeting.

“The results of the ratification were as follows: FOR AGAINST ABSTAIN 84,619,141 2,888 2”

Tango Therapeutics, Inc. shareholders approved Election of two Class II director nominees to the Board of Directors at the 2023-06-06 meeting.

“The results of the election were as follows: CLASS II DIRECTOR NOMINEE FOR WITHHELD BROKER NON-VOTES Malte Peters, M.D. 75,943,817 3,532,483 5,145,731 Mace Rothenberg, M.D. 76,746,614 2,729,682 5,145,731”

Tango Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2023.

“Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2023, and provided business highlights.”

Tango Therapeutics, Inc. reported financial results for the full year ended December 31, 2022.

“Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2022, and provided business highlights.”

Tango Therapeutics, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $6.4 million.

“Collaboration revenue was $6.4 million for the three months ended December 31, 2022”

Adam Crystal was appointed as President, Research & Development at Tango Therapeutics, Inc..

“On February 28, 2023, Tango Therapeutics, Inc. (“Tango” or the “Company”) announced that Adam Crystal, M.D., Ph.D., 46 years old, was appointed as the Company’s President, Research & Development, effective as of February 27, 2023.”

Tango Therapeutics, Inc. reported third quarter ended September 30, 2022 results: revenue $6.9 million.

“held $393.3 million in cash, cash equivalents and marketable securities, which the Company believes to be sufficient to fund operations into 2025. Collaboration revenue was $6.9 million for the three months ended September 30, 2022, compared to $6.8 million for the same period in 2021, and $18.4 million for the nine months ended September 30, 2022 compared to”

Barbara Weber was appointed as Director at Tango Therapeutics, Inc..

“Lesley Calhoun and Reid Huber were appointed as Class I directors, Malte Peters and Mace Rothenberg were appointed as Class II directors and Alexis Borisy, Aaron Davis and Barbara Weber were appointed as Class III directors.”

Aaron Davis was appointed as Director at Tango Therapeutics, Inc..

“Lesley Calhoun and Reid Huber were appointed as Class I directors, Malte Peters and Mace Rothenberg were appointed as Class II directors and Alexis Borisy, Aaron Davis and Barbara Weber were appointed as Class III directors.”

Alexis Borisy was appointed as Director at Tango Therapeutics, Inc..

“Lesley Calhoun and Reid Huber were appointed as Class I directors, Malte Peters and Mace Rothenberg were appointed as Class II directors and Alexis Borisy, Aaron Davis and Barbara Weber were appointed as Class III directors.”

Mace Rothenberg was appointed as Director at Tango Therapeutics, Inc..

“Lesley Calhoun and Reid Huber were appointed as Class I directors, Malte Peters and Mace Rothenberg were appointed as Class II directors and Alexis Borisy, Aaron Davis and Barbara Weber were appointed as Class III directors.”

Malte Peters was appointed as Director at Tango Therapeutics, Inc..

“Lesley Calhoun and Reid Huber were appointed as Class I directors, Malte Peters and Mace Rothenberg were appointed as Class II directors and Alexis Borisy, Aaron Davis and Barbara Weber were appointed as Class III directors.”

Reid Huber was appointed as Director at Tango Therapeutics, Inc..

“Lesley Calhoun and Reid Huber were appointed as Class I directors, Malte Peters and Mace Rothenberg were appointed as Class II directors and Alexis Borisy, Aaron Davis and Barbara Weber were appointed as Class III directors.”

Lesley Calhoun was appointed as Director at Tango Therapeutics, Inc..

“Lesley Calhoun and Reid Huber were appointed as Class I directors, Malte Peters and Mace Rothenberg were appointed as Class II directors and Alexis Borisy, Aaron Davis and Barbara Weber were appointed as Class III directors.”